Drug Trial Radar · NCT06561607
A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
542
Planned (sponsor's estimate)
Start
Oct 11, 2024
Primary completion
Jan 2027
Study completion Dec 2028
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 20, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a Phase III, randomized, multicenter, open-label study in HER2-low, HR+ metastatic breast cancer subjects who are patients with locally advanced or metastatic breast cancer with low HER2 expression in the recurrent metastatic stage who have not received chemotherapy. The primary objective of the study is to determine the efficacy and safety of TQB2102 compared to investigator-selected single-agent chemotherapy in the target population. 542 subjects with HER2 immunohistochemistry (IHC )2+/ in situ hybridization (ISH)- and IHC 1+ (HER2-low) expression will be enrolled in 1:1 randomized groups to receive TQB2102 or investigator's choice of single-agent chemotherapy (capecitabine, paclitaxel, or albumin-paclitaxel) until progression of disease (PD), as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1. 1, unless there are unacceptable toxicity, withdrawal of consent, or meeting other discontinuation criteria.
Conditions
- Breast Cancer
Interventions
TQB2102 for InjectionDrug
TQB2102 is a next-generation HER2 Antibody-Drug Conjugate (ADC) drug proposed for patients with HER2 low-expressing breast cancer.
Chemotherapy drug (Capecitabine/Paclitaxel/Albumin Paclitaxel)Drug
Based on each patient's condition and previous treatment history, the investigator will select one of the chemotherapy drugs for treatment. * Capecitabine: 1000-1250 mg/m2 twice daily, administered consecutively on day 1-14, 21 days as a treatment cycle. * Paclitaxel: 175 mg/m2, IV infusion, administered Day1 per cycle, 21 days as a treatment cycle. OR 80 mg/m2 by IV infusion administered weekly. * Albumin Paclitaxel: 260 mg/m2, IV infusion, administered every cycle of Day1 for 21 days as a treatment cycle. 100 mg/m2 or 125 mg/m2, IV infusion, administered every cycle of Day 1 and Day 8 for 21 days as a treatment cycle; or Day 1, Day 8, and Day 15 administered every cycle for 28 days as a treatment cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS) in subjects with HR-positive, HER2 low-expressing recurrent/metastatic breast cancer as assessed by Independent Review Committee (IRC)Time frame: Up to 25 months
Locations
34 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Bengbu Medical University
Bengbu, Anhui, China
AnHui Province Hospital West District
Hefei, Anhui, China
The first Affiliated hospital of anhui medical university
Hefei, Anhui, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Fujian Medical University 2nd Affiliated Hospital
Quanzhou, Fujian, China
Zhangzhou Hospital in Fujian Province
Zhangzhou, Fujian, China
Gansu Provincial Hospital
Lanzhou, Gansu, China
Gansu Provincial Cancer Hospital
Lanzhou, Gansu, China
Gansu Wuwei Tumour Hospital
Wuwei, Gansu, China
Sun Yet-Sen University Cancer Certer
Guangzhou, Guangdong, China
Affiliated Hospital of Guangdong Medical University
Zhanjiang, Guangdong, China
Guigang City People'S Hospital
Guigang, Guangxi, China
Cancer Hospital Affiliated to Guangxi Medical University
Nanning, Guangxi, China
The First affiliated hospital of GuangXi medical university
Nanning, Guangxi, China
The Affiliated Cancer Hospital of Guizhou Medical University Co., LTD
Guiyang, Guizhou, China
Guizhou Provincial People's Hospital
Guiyang, Guizhou, China
The First Affiliated Hospital of Hainan Medical College
Haikou, Hainan, China
Hainan General Hospital
Haikou, Hainan, China
Affiliated Hospital of Hebei University
Baoding, Hebei, China
Chengde Central Hospital
Chengde, Hebei, China
Affiliated Cancer Hospital of Harbin Medical University
Harbin, Heilongjiang, China
AnYang Tumor Hospital
Anyang, Henan, China
Henan Cancar Hospital
Zhengzhou, Henan, China
The First Affiliated Hospital of Henan University of Science & Technology
Luoyang, Hennan, China
Tongji Hospital Tongji Medical College of HUST
Wuhan, Hubei, China
Hubei Cancer Hospital
Wuhan, Hubei, China
Chifeng Municipal Hospital
Chifeng, Inner Mongolia, China
The Second Hospital of DALIAN Medical University
Dalian, Liaoning, China
Binzhou Medical College Affiliated Hospital
Binzhou, Shandong, China
Binzhou People's Hospital
Binzhou, Shandong, China
Obstetrics & Gynecology Hospital of Fudan University
Shanghai, Shanghai Municipality, China
Baoji Central Hospital
Baoji, Shanxi, China
Affiliated Hospital of North Scichuan Medical College
Nanchong, Sichuan, China
Affiliated Hangzhou First People's Hospital
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.